A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

Background: This randomized phase III study compared the overall survival (OS) of pemetrexed plus gemcitabine (PG) versus standard gemcitabine (G) in patients with advanced pancreatic cancer. Patients and methods: Patients with unresectable locally advanced or metastatic pancreatic cancer and no pri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2005-10, Vol.16 (10), p.1639-1645
Hauptverfasser:	Oettle, H., Richards, D., Ramanathan, R. K., van Laethem, J. L., Peeters, M., Fuchs, M., Zimmermann, A., John, W., Von Hoff, D., Arning, M., Kindler, H. L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Gastroenterology. Liver. Pancreas. Abdomen gemcitabine Glutamates - administration & dosage Guanine - administration & dosage Guanine - analogs & derivatives Humans Infusions, Intravenous Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Neoplasm Metastasis Neutropenia - chemically induced pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Pemetrexed Pharmacology. Drug treatments phase III survival Survival Analysis Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!